Filing Flows › Alpha Teknova (TKNO) › Q3 2026 › vs Q3 2025
Alpha Teknova (TKNO) Q3 2026 vs Q3 2025 (year over year)
Alpha Teknova's revenue rose $2.2M (+22%) from $10.5M in Q3 2025 to $12.7M in Q3 2026. The biggest changes: Clinical Solutions +$1.5M (+86%); Lab Essentials +$726K (+9%); Other Product +$62K (+14%).
Alpha Teknova, Q3 2026: revenue $12.7M (+22% year over year), operating margin -25.2%, net loss $3.5M, operating cash flow −$1.3M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Lab Essentials | $9.0M | $8.3M | $726K | +9% |
| Clinical Solutions | $3.2M | $1.7M | $1.5M | +86% |
| Other Product | $502K | $440K | $62K | +14% |
| Revenue | $12.7M | $10.5M | $2.2M | +22% |
| Net loss | $3.5M | $4.3M | −$796K | -19% |
| Costs & expenses | $16.2M | $14.7M | $1.5M | +10% |
| Operating costs | $15.9M | $14.5M | $1.4M | +10% |
| Interest & other, net | $250K | $190K | $60K | +32% |
| Income tax | $34K | $79K | −$45K | -57% |
| Cost of revenue | $7.9M | $7.2M | $630K | +9% |
| Research & development | $581K | $542K | $39K | +7% |
| Sales & marketing | $2.3M | $1.7M | $601K | +34% |
| General & admin | $4.8M | $4.6M | $169K | +4% |
| Other operating costs | $287K | $287K | $0 | 0% |
| Operating cash sources | $3.5M | $4.3M | −$796K | -19% |
| Depreciation & amortization | $1.6M | $1.6M | −$2K | -0.1% |
| Share-based compensation | $612K | $850K | −$238K | -28% |
| Working capital & other | $11K | −$135K | $146K | — |
| Cash used in operations | $1.3M | $2.0M | −$702K | -35% |
| Net loss absorbed | $3.5M | $4.3M | −$796K | -19% |
Questions
How much did Alpha Teknova's revenue grow year over year in Q3 2026?
Alpha Teknova's revenue rose $2.2M (+22%) from $10.5M in Q3 2025 to $12.7M in Q3 2026.
What drove Alpha Teknova's revenue change in Q3 2026?
Clinical Solutions +$1.5M (+86%); Lab Essentials +$726K (+9%); Other Product +$62K (+14%).